Results 51 to 60 of about 5,671 (151)
Clinical and Translational Science, Volume 19, Issue 11, November 2026.
Paridhi Gupta +3 more
wiley +1 more source
ABSTRACT Background The introduction of novel androgen receptor signaling inhibitors (ARSIs) has substantially transformed the systemic treatment landscape for non‐metastatic castration‐resistant prostate cancer (nmCRPC). Unfortunately, ARSI therapy is associated with considerable adverse events (AEs) and high medical costs.
Himawari Asanuma +18 more
wiley +1 more source
The recently published phase II prospective SWITCH trial evaluated whether patients with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone acetate could benefit from a ‘steroid switch’ from prednisone to dexamethasone.
Elisa Zanardi +4 more
doaj +1 more source
Background The value of continuation of luteinizing hormone-releasing hormone (LHRH) therapy in castration-resistant prostate cancer (CRPC) remains controversial and clear evidence is lacking.
Carsten-Henning Ohlmann +6 more
doaj +1 more source
This study demonstrates that transcription factor androgen receptor (AR) directly binds the LF promoter, driving lactoferrin overexpression to promote ferritin (FTH1/FTL) upregulation and inhibit p53‐ALOX12‐mediated ferroptosis in prostate cancer. Lactoferrin could be a new potential therapeutic target in prostate cancer.
Can Liu +18 more
wiley +1 more source
ABSTRACT Introduction Neuroendocrine prostate cancer is a rare and highly aggressive variant of prostate cancer with a poor prognosis. We report a case in which metastatic castration‐sensitive prostate cancer directly transformed into neuroendocrine prostate cancer without a corresponding increase in prostate‐specific antigen.
Yoshihiro Nakagami +9 more
wiley +1 more source
ABSTRACT Introduction The combination of enzalutamide and radium‐223 has demonstrated clinical efficacy in metastatic castration‐resistant prostate cancer; however, real‐world evidence remains limited, particularly with PSA–discordant progression. Case Presentation A 74‐year‐old man with high‐risk localized prostate cancer was treated with androgen ...
Yamato Numata +9 more
wiley +1 more source
BACKGROUND: Abiraterone acetate is an effective drug for castration-resistant prostate cancer, but cardiac serious adverse events (SAEs) may occur. We studied their association with N-terminal pro–brain natriuretic peptide (NT-proBNP) and troponin T (TnT)
Sara Campora +19 more
doaj +1 more source
Platelet to lymphocyte ratio (PLR) is a candidate prognostic marker for metastatic castration‐resistant prostate cancer patients receiving abiraterone acetate and evidence demonstrates that a high PLR is associated with poor survival.
Oliver E. Yausep +7 more
doaj +1 more source

